Not available
Quote | Karo Pharma Aktiebolag (OTCMKTS:KARBF)
Last: | $5.25 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $5.25 |
High: | $0 |
Low: | $0 |
Volume: | 100 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Karo Pharma Aktiebolag (OTCMKTS:KARBF)
HUDDINGE, Sweden , July 21, 2020 /PRNewswire/ -- Q2, April - June Net sales amounted to MSEK 688.9 (387.4). This corresponds to an increase of 78% for the period. The organic growth during the second quarter was -10%, currency impact 0% and 88% relates to the acquisition of ...
HUDDINGE, Sweden , May 26, 2020 /PRNewswire/ -- At today's annual general meeting of Karo Pharma, the following decisions were passed. The annual general meeting resolved to adopt the income statement and balance sheet for the group and the parent company. The annual general meeting res...
Message Board Posts | Karo Pharma Aktiebolag (OTCMKTS:KARBF)
Subject | By | Source | When |
---|---|---|---|
chartguy89: KARBF 0.10 Stock Charts $KARBF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 7:47:53 AM |
chartguy89: KARBF Stock Charts Last: +0.04 Thursday, February 27, 2014 at 9:24:23 AM $KARBF | chartguy89 | investorshangout | 02/27/2014 2:24:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Karo Pharma Aktiebolag Company Name:
KARBF Stock Symbol:
OTCMKTS Market:
HUDDINGE, Sweden , July 21, 2020 /PRNewswire/ -- Q2, April - June Net sales amounted to MSEK 688.9 (387.4). This corresponds to an increase of 78% for the period. The organic growth during the second quarter was -10%, currency impact 0% and 88% relates to the acquisition of ...
HUDDINGE, Sweden , May 26, 2020 /PRNewswire/ -- At today's annual general meeting of Karo Pharma, the following decisions were passed. The annual general meeting resolved to adopt the income statement and balance sheet for the group and the parent company. The annual general meeting res...
HUDDINGE, Sweden , May 8, 2020 /PRNewswire/ -- Karo Pharma Aktiebolag ("Karo Pharma") today announces the signing and closing of the acquisition of the remaining European rights to the Pevaryl ® brand portfolio from Cilag GmbH International, one of the Janssen Pharmaceutical C...